Palisade Bio, Inc. (PALI)
2.01
-0.04
(-1.95%)
USD |
NASDAQ |
Sep 10, 16:00
2.05
+0.04
(+1.99%)
After-Hours: 20:00
Palisade Bio Enterprise Value : 223.76M for Sept. 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 10, 2026 | 223.76M |
| September 09, 2026 | 230.70M |
| September 08, 2026 | 256.74M |
| September 04, 2026 | 237.64M |
| September 03, 2026 | 229.83M |
| September 02, 2026 | 220.28M |
| September 01, 2026 | 215.08M |
| August 31, 2026 | 213.34M |
| August 28, 2026 | 222.02M |
| August 27, 2026 | 241.12M |
| August 26, 2026 | 244.59M |
| August 25, 2026 | 234.17M |
| August 24, 2026 | 223.76M |
| August 21, 2026 | 239.38M |
| August 20, 2026 | 232.44M |
| August 19, 2026 | 249.80M |
| August 18, 2026 | 228.96M |
| August 17, 2026 | 248.06M |
| August 14, 2026 | 246.32M |
| August 13, 2026 | 248.06M |
| August 12, 2026 | 215.08M |
| August 11, 2026 | 246.32M |
| August 10, 2026 | 239.38M |
| August 07, 2026 | 241.12M |
| August 06, 2026 | 237.64M |
| Date | Value |
|---|---|
| August 05, 2026 | 242.85M |
| August 04, 2026 | 234.17M |
| August 03, 2026 | 211.60M |
| July 31, 2026 | 203.79M |
| July 30, 2026 | 215.08M |
| July 29, 2026 | 215.08M |
| July 28, 2026 | 225.49M |
| July 27, 2026 | 227.23M |
| July 24, 2026 | 213.34M |
| July 23, 2026 | 225.49M |
| July 22, 2026 | 204.66M |
| July 21, 2026 | 208.13M |
| July 20, 2026 | 206.40M |
| July 17, 2026 | 216.81M |
| July 16, 2026 | 202.92M |
| July 15, 2026 | 227.23M |
| July 14, 2026 | 209.87M |
| July 13, 2026 | 202.92M |
| July 10, 2026 | 215.08M |
| July 09, 2026 | 216.81M |
| July 08, 2026 | 230.70M |
| July 07, 2026 | 235.91M |
| July 06, 2026 | 228.96M |
| July 02, 2026 | 239.38M |
| July 01, 2026 | 216.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.892B |
| Alnylam Pharmaceuticals, Inc. | 32.78B |
| Anika Therapeutics, Inc. | 267.75M |
| Savara, Inc. | 950.10M |
| Vericel Corp. | 1.870B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.57M |
| Revenue (Quarterly) | 0.50M |
| Total Expenses (Quarterly) | 11.07M |
| EPS Diluted (Quarterly) | -0.05 |
| Profit Margin (Quarterly) | -2.11K% |
| Earnings Yield | -26.63% |
| Normalized Earnings Yield | -28.19 |